The OIG has released a report from its February 23, 2012, government-industry “Pharmaceutical Compliance Roundtable.” The Roundtable was convened to allow OIG representatives to discuss with pharmaceutical industry compliance professionals their experiences under corporate integrity agreements (CIAs) and with various types of compliance activities. Specific topics of discussion included: challenges in implementing CIAs; compliance program structure and oversight; risk assessment and monitoring activities; policies, procedures, and training activities; and compliance post-CIA.